Celgene Corporation gets USFDA approves for REVLIMID
The approval was based on the results of MCL-001, a phase II, multi-center, single arm, open label study evaluating lenalidomide in 134 patients with MCL who had received prior treatment with rituximab, cyclophosphamide, an anthracycline (or ...
FDA Approves Lenalidomide for the Treatment of Mantle Cell LymphomaOncLive
Revlimid Gains New Lymphoma IndicationMonthly Prescribing Reference
FDA clears Celgene's sNDA for mantle cell lymphoma drug candidatePharmaceutical Business Review

all 16 news articles »